Key statistics
On Thursday, Stoke Therapeutics Inc (0GT:DEU) closed at 11.00, -33.73% below its 52-week high of 16.60, set on Jun 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.60 |
---|---|
High | 11.10 |
Low | 10.60 |
Bid | 10.60 |
Offer | 10.90 |
Previous close | 10.90 |
Average volume | 25.00 |
---|---|
Shares outstanding | 52.97m |
Free float | 50.59m |
P/E (TTM) | -- |
Market cap | 596.94m USD |
EPS (TTM) | -2.10 USD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Press releases
- Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
- Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
- Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
- Stoke Therapeutics to Present at Upcoming Investor Conferences in September
- Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
More ▼